<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00086216</url>
  </required_header>
  <id_info>
    <org_study_id>CP-101</org_study_id>
    <secondary_id>efficacy</secondary_id>
    <secondary_id>pharmacokinetics</secondary_id>
    <secondary_id>research markers</secondary_id>
    <nct_id>NCT00086216</nct_id>
    <nct_alias>NCT00301977</nct_alias>
    <nct_alias>NCT00491972</nct_alias>
  </id_info>
  <brief_title>Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma</brief_title>
  <official_title>An Open-Label Study of the Safety and Efficacy of Atiprimod Treatment for Patients With Refractory or Relapsed Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Callisto Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Callisto Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I/IIa clinical trial to identify the maximum tolerated dose of atiprimod and&#xD;
      to evaluate the safety of atiprimod in patients with refractory or relapsed multiple myeloma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, dose escalation study intended to identify the MTD of&#xD;
      atiprimod alone and the MTD of atiprimod when given in combination with ursodiol. The&#xD;
      atiprimod dose will be escalated in sequential cohorts. Ten dose levels of atiprimod are&#xD;
      planned for the atiprimod alone dose escalation: 30, 60, 90, 120, 180, 240, 300, 360, 420,&#xD;
      and 480 mg/day to be given orally. Six dose levels of atiprimod are planned for the atiprimod&#xD;
      in combination with ursodiol dose escalation: 180, 240, 300, 360, 420, and 480 mg/day to be&#xD;
      given orally. The dose of ursodiol will remain constant for all cohorts (300 mg ursodiol&#xD;
      orally three times a day everyday). Up to 105 patients will participate depending on the&#xD;
      level at which toxicity is observed. Patients will be assigned to dose level in the order of&#xD;
      study entry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to identify the maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary objective of this study is to measure the pharmacokinetics of</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atiprimod</intervention_name>
    <description>Oral, once a day, 14 days on 14 days off</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  documented history of multiple myeloma,&#xD;
&#xD;
          -  failed at least two prior regimens for multiple myeloma,&#xD;
&#xD;
          -  18 years of age or older,&#xD;
&#xD;
          -  ECOG(Zubrod)PS of 0 to 2,&#xD;
&#xD;
          -  screening evaluation for determining eligibility prior to enrollment,&#xD;
&#xD;
          -  signed informed consent form,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  concomitant therapy medications including corticosteroids or other chemotherapy that&#xD;
             is or may be active against myeloma ,&#xD;
&#xD;
          -  renal insufficiency (serum creatinine levels of &gt; 2mg/dL),&#xD;
&#xD;
          -  mucosal bleeding,&#xD;
&#xD;
          -  any condition which in the opinion of the Investigator, places the patient at&#xD;
             unacceptable risk if he/she were to participate in the study.&#xD;
&#xD;
          -  clinically relevant active infection or co-morbid medical conditions.&#xD;
&#xD;
          -  prior malignancy(within the last 3 years) except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, in situ cervical cancer, or other cancer for which the&#xD;
             patient is has been disease-free for at least 3 years.&#xD;
&#xD;
          -  patients with non-secretory myeloma.&#xD;
&#xD;
          -  as atiprimod is a potent inhibitor or CYP2D6, patients taking drugs that are&#xD;
             substrates of CYP2D6(e.g. beta blockers, antidepressants and antipsychotics) will be&#xD;
             excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Jacob, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Callisto Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <study_first_submitted>June 28, 2004</study_first_submitted>
  <study_first_submitted_qc>June 29, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2004</study_first_posted>
  <last_update_submitted>December 20, 2007</last_update_submitted>
  <last_update_submitted_qc>December 20, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2007</last_update_posted>
  <responsible_party>
    <name_title>Gary Jacob</name_title>
    <organization>Callisto Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

